WELLFITXPLORE 2025 CONCLUDES WITH GREAT SUCCESS: ADVANCING THE "HEALTHY MACAO BLUEPRINT" AND BUILDING A BENCHMARK PLATFORM FOR HEALTH AND WELLNESS IN THE ASIA-PACIFIC
MACAO, Nov. 24, 2025 /PRNewswire/ -- From November 22 to 23, WellFitXplore 2025—the Asia-Pacific Health & Wellness Training Festival—was successfully held at MGM COTAI in Macao. Organized by CrossFit China and proudly sponsored by MGM, this...
Five-Year Plans: A Key Approach of the CPC's Governance of China
BEIJING, Nov. 24, 2025 /PRNewswire/ -- A news report from en.qstheory.cn Formulating medium- and long-term plans to guide economic and social development is an important approach with which the Communist Party of China (CPC) governs the country. As...
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation,...
Appotronics Touts Laser+LCoS As Key to Revolutionizing AR Glasses Experience at LIPA 2025
NEW YORK, Nov. 24, 2025 /PRNewswire/ -- At the Laser Illuminated Projector Association (LIPA) 2025 annual general meeting, Appotronics, the inventor of ALPD® laser display technology and a board member of the organization, detailed the compelling...
Testsigma Releases Atto 2.0, Advancing Autonomous Testing for Modern Software Teams
SAN FRANCISCO, Nov. 21, 2025 /PRNewswire/ -- Testsigma, one of the fastest-growing AI-powered software testing platforms, has introduced Atto 2.0, a major advancement in autonomous testing that helps QA teams keep pace with the speed and complexity...
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its...
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
SYDNEY, Nov. 19, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an FDA-authorized...
Artificial Intelligence Association of Hong Kong (AIHK) Annual Conference 2025: Building a Global Center of Excellence (CoE) for Artificial Intelligence
HONG KONG, Nov. 18, 2025 /PRNewswire/ -- The Artificial Intelligence Association of Hong Kong (AIHK) convenes its inaugural Annual Conference, celebrating a year of remarkable achievement and future vision as a Global Center of Excellence (CoE) for...
Locksley Enters into Sponsored Research Agreement with Columbia University to Develop Advanced Sustainable Processing Technologies for Rare Earth Elements (REE) and Critical Metal Recovery
SAN BERNARDINO, Calif., Nov. 17, 2025 /PRNewswire/ -- Locksley Resources, Ltd. (ASX: LKY; OTCQX: LKYRF) announced the company has formalized a research collaboration with Columbia University, one of the United States' premier institutions in...
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical...